Morepen Laboratories enters US prescription generics market

Morepen Laboratories Limited gained 5% to ₹99.15 after launching its first prescription generic drug in the US, ending an eight-session losing streak. The company has introduced Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs through its wholly owned US subsidiary, Morepen Bio Inc. This marks its transition from supplying active pharmaceutical ingredients (APIs) to distributing finished-dose prescription medicines in the US. Morepen has already supplied Desloratadine API to the US market for several years. It has also submitted its first Abbreviated New Drug Application (ANDA) to the US FDA for Sitagliptin Phosphate Tablets in 25 mg, 50 mg and 100 mg strengths. The company plans further generic drug filings and may also pursue opportunities in high-potency APIs and oncology. My view: The bigger development is the shift towards finished-dose generics rather than the launch of a single product. Morepen already has API relationships in the US, which could help it build distribution opportunities. However, the financial contribution will depend on product volumes, pricing, regulatory approvals and the company's ability to secure repeat orders. The Sitagliptin ANDA is another development to track, but an application submission does not guarantee approval or commercial success. The stock has gained 141.18% so far in 2026, making valuation and earnings delivery important considerations. I would watch for further FDA approvals, new product launches and revenue contribution from the US business before taking a stronger positive view. My stance: Positive on the business expansion, but sustained earnings growth and execution will be key to supporting the stock's valuation. MOREPENLAB Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.